Cabio Biotech Wuhan Stock Total Asset
| 688089 Stock | 18.09 0.25 1.40% |
Cabio Biotech Wuhan fundamentals help investors to digest information that contributes to Cabio Biotech's financial success or failures. It also enables traders to predict the movement of Cabio Stock. The fundamental analysis module provides a way to measure Cabio Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cabio Biotech stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 1.9 B | 1.2 B |
Cabio | Total Asset |
Cabio Biotech Wuhan Company Total Asset Analysis
Cabio Biotech's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Cabio Biotech Total Asset | 1.61 B |
Most of Cabio Biotech's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cabio Biotech Wuhan is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Cabio Total Assets
Total Assets |
|
Based on the latest financial disclosure, Cabio Biotech Wuhan has a Total Asset of 1.61 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all China stocks is notably lower than that of the firm.
Cabio Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cabio Biotech's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cabio Biotech could also be used in its relative valuation, which is a method of valuing Cabio Biotech by comparing valuation metrics of similar companies.Cabio Biotech is currently under evaluation in total asset category among its peers.
Cabio Fundamentals
| Return On Equity | 0.0733 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 2.86 B | ||||
| Shares Outstanding | 168.31 M | ||||
| Shares Owned By Insiders | 50.75 % | ||||
| Shares Owned By Institutions | 4.86 % | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 5.98 X | ||||
| Revenue | 443.8 M | ||||
| Gross Profit | 179.62 M | ||||
| EBITDA | 160.2 M | ||||
| Net Income | 91.37 M | ||||
| Total Debt | 12.1 M | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | 68.89 M | ||||
| Earnings Per Share | 0.68 X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 508 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 3.02 B | ||||
| Total Asset | 1.61 B | ||||
| Retained Earnings | 421.34 M | ||||
| Working Capital | 596.35 M | ||||
| Net Asset | 1.61 B | ||||
| Last Dividend Paid | 0.2 |
About Cabio Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cabio Biotech Wuhan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cabio Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cabio Biotech Wuhan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Cabio Stock
Cabio Biotech financial ratios help investors to determine whether Cabio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cabio with respect to the benefits of owning Cabio Biotech security.